Our NCG portfolio is one of the most comprehensive sets of immunodeficient mouse models available for both non-profit and for-profit users, making it ideal for cancer immunotherapy research using cell derived xenograft (CDX), patient derived xenograft (PDX), and immune system reconstitution using human peripheral blood mononuclear cells (PBMC) as well as human hematopoietic stem cells (HSC). NCG and all strains of next-generation NCG mice are developed using gene editing technology on pure inbred NOD/ShiLtJGpt background, by knocking out the Prkdc (Protein kinase, DNA activated, catalytic polypeptide) and Il2rg (interleukin-2 receptor subunit gamma) genes. Currently, we have more than 100 cell derived xenografts (CDXs) to accompany our NCG strains utilized in preclinical efficacy and safety studies.
